Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials

被引：21

作者：

Felip, E. ^{[1
]}

Crino, L. ^{[2
]}

Kim, D. -W. ^{[3
]}

Spigel, D. R. ^{[4
]}

Nishio, M. ^{[5
]}

Mok, T. ^{[6
]}

Scagliotti, G. ^{[7
]}

Cesic, D. ^{[8
]}

Sutradhar, S. ^{[9
]}

Shaw, A. T. ^{[10
]}

机构：

[1] Vail dHebron Univ Hosp, Inst Oncol, Med Oncol Serv, Barcelona, Spain

[2] Osped S Maria Misericordia, Oncol Med, Perugia, Italy

[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[4] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA

[5] JFCR, Canc Inst Hosp, Thorac Med Oncol, Tokyo, Japan

[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China

[7] Univ Turino, Oncol, Turin, Italy

[8] Novartis Pharmaceut, GMA Oncol, E Hanover, NJ USA

[9] Novartis Pharmaceut, GMA Biostat, E Hanover, NJ USA

[10] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 04期

关键词：

D O I：

10.1016/S1556-0864(16)30251-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

141PD

引用

页码：S118 / S119

页数：2

共 50 条

[1] Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3
Park, K.
Tan, D.
Ahn, M. -J.
Yu, C. -J.
Tsai, C. -M.
Hida, T.
Nishio, M.
Branle, F.
Emeremni, C.
Mok, T.
ANNALS OF ONCOLOGY, 2015, 26 : 126 - 127
[2] Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
Thomas, M.
Schuler, M.
Potzner, M.
Szczudlo, T.
Sutradhar, S.
Yovine, A.
Wolf, J.
Oncology Research and Treatment, 2015, 38 : 270 - 270
[3] WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK plus ) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND-3
Mehra, Ranee
Felip, Enriqueta
Tan, Daniel Shao-Weng
Kim, Dong-Wan
Orlov, Sergey
Park, Keunchil
Yu, Chong-Jen
Mok, Tony
Nishio, Makoto
Scagliotti, Giorgio V.
Spigel, David R.
Sutradhar, Santosh
Cesic, Dajana
Shaw, Alice Tsang
NEURO-ONCOLOGY, 2016, 18 : 28 - 29
[4] Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK plus ) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and-3.
Felip, Enriqueta
Tan, Daniel Shao-Weng
Kim, Dong-Wan
Mehra, Ranee
Orlov, Sergey
Park, Keunchil
Yu, Chong-Jen
Mok, Tony
Nishio, Makoto
Scagliotti, Giorgio V.
Spigel, David R.
Sutradhar, Santosh
Cesic, Dajana
Shaw, Alice Tsang
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL
Shaw, Alice
Mehra, Ranee
Tan, Daniel S. W.
Felip, Enriqueta
Chow, Laura Q. M.
Camidge, D. Ross
Vansteenkiste, Johan
Sharma, Sunil
De Pas, Tommaso
Riely, Gregory J.
Solomon, Benjamin J.
Wolf, Juergen
Thomas, Michael
Schuler, Martin
Liu, Geoffrey
Santoro, Armando
Geraldes, Margarida
Sen, Paramita
Boral, Anthony J.
Yovine, Alejandro
Kim, Dong-Wan
NEURO-ONCOLOGY, 2014, 16
[6] Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial
Kim, Dong-Wan
Mehra, Ranee
Tan, Daniel Shao-Weng
Felip, Enriqueta
Chow, Laura Quan Man
Camidge, D. Ross
Vansteenkiste, Johan F.
Sharma, Sunil
De Pas, Tommaso
Riely, Gregory J.
Solomon, Benjamin J.
Wolf, Juergen
Thomas, Michael
Schuler, Martin H.
Liu, Geoffrey
Santoro, Armando
Geraldes, Margarida
Boral, Anthony
Yovine, Alejandro Javier
Shaw, Alice Tsang
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1
Kim, D.
Mehra, R.
Tan, D. S. W.
Felip, E.
Chow, L. Q. M.
Camidge, D. R.
Vansteenkiste, J.
Sharma, S.
De Pas, T.
Riely, G. J.
Solomon, B. J.
Wolf, J.
Thomas, M.
Schuler, M.
Liu, G.
Santoro, A.
Geraldes, M.
Boral, A. L.
Yovine, A.
Shaw, A. T.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S33 - S34
[8] ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).
Mok, Tony
Spigel, David
Felip, Enriqueta
deMarinis, Filippo
Ahn, Myung-Ju
Groen, Harry J. M.
Wakelee, Heather A.
Hida, Toyoaki
Crino, Lucio
Nishio, Makoto
Scagliotti, Giorgio V.
Branle, Fabrice
Emeremni, Chetachi
Quadrigli, Massimiliano
Zhang, Jie
Shaw, Alice Tsang
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[9] Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
Tan, D. S-W.
Thomas, M.
Kim, D-W.
Szpakowski, S.
Urban, P.
Mehra, R.
Chow, L. Q. M.
Sharma, S.
Solomon, B. J.
Felip, E.
Camidge, D. R.
Vansteenkiste, J.
Petruzzelli, L.
Pantano, S.
Shaw, A. T.
LUNG CANCER, 2022, 163 : 7 - 13
[10] Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naive Patients with ALK plus NSCLC and Brain Metastases: Results of ASCEND 1 and 3
Shaw, Alice T.
Spigel, David R.
Tan, Daniel S. -W.
Kim, Dong-Wan
Mehra, Ranee
Orlov, Sergey
Park, Keunchil
Yu, Chong-Jen
Mok, Tony
Nishio, Makoto
Scagliotti, Giorgio
Sutradhar, Santosh
Cesic, Dajana
Felip, Enriqueta
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S256 - S256

← 1 2 3 4 5 →